Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation

Por San Miguel, J F, Mateos, M-V
Publicado no Leukemia Suppl (2013)

Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Por Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C
Publicado no Leukemia (2018)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Por Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., Anderson, K. C.
Publicado no Leukemia (2019)

Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes

Por Hari, P, Mateos, M-V, Abonour, R, Knop, S, Bensinger, W, Ludwig, H, Song, K, Hajek, R, Moreau, P, Siegel, D S, Feng, S, Obreja, M, Aggarwal, S K, Iskander, K, Goldschmidt, H
Publicado no Leukemia (2017)

Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma

Por Dimopoulos, M A, Leleu, X, Palumbo, A, Moreau, P, Delforge, M, Cavo, M, Ludwig, H, Morgan, G J, Davies, F E, Sonneveld, P, Schey, S A, Zweegman, S, Hansson, M, Weisel, K, Mateos, M V, Facon, T, Miguel, J F S
Publicado em 2014

Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma

Por Martinez-Lopez, J, Sanchez-Vega, B, Barrio, S, Cuenca, I, Ruiz-Heredia, Y, Alonso, R, Rapado, I, Marin, C, Cedena, M-T, Paiva, B, Puig, N, Mateos, M-V, Ayala, R, Hernández, M-T, Jimenez, C, Rosiñol, L, Martínez, R, Teruel, A-I, Gutiérrez, N, Martin-Ramos, M-L, Oriol, A, Bargay, J, Bladé, J, San-Miguel, J, Garcia-Sanz, R, Lahuerta, J-J
Publicado no Leukemia (2017)

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

Por Sanoja-Flores, L., Flores-Montero, J., Garcés, J. J., Paiva, B., Puig, N., García-Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., Hernández-Martín, J., Pontes, R., Díez-Campelo, M., Millacoy, P., Rodríguez-Otero, P., Prosper, F., Merino, J., Vidriales, M. B., García-Sanz, R., Romero, A., Palomera, L., Ríos-Tamayo, R., Pérez-Andrés, M., Blanco, J. F., González, M., van Dongen, J. J. M., Durie, B., Mateos, M. V., San-Miguel, J., Orfao, A.
Publicado no Blood Cancer J (2018)

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

Por Flores-Montero, J, Sanoja-Flores, L, Paiva, B, Puig, N, García-Sánchez, O, Böttcher, S, van der Velden, V H J, Pérez-Morán, J-J, Vidriales, M-B, García-Sanz, R, Jimenez, C, González, M, Martínez-López, J, Corral-Mateos, A, Grigore, G-E, Fluxá, R, Pontes, R, Caetano, J, Sedek, L, del Cañizo, M-C, Bladé, J, Lahuerta, J-J, Aguilar, C, Bárez, A, García-Mateo, A, Labrador, J, Leoz, P, Aguilera-Sanz, C, San-Miguel, J, Mateos, M-V, Durie, B, van Dongen, J J M, Orfao, A
Publicado no Leukemia (2017)